Abstract
DNA methylation (DNAm) is an epigenetic mark with essential roles in disease development and predisposition. Here, we created genome-wide maps of methylation quantitative trait loci (meQTL) in three peripheral tissues and used Mendelian randomization (MR) analyses to assess the potential causal relationships between DNAm and risk for two common neurodegenerative disorders, i.e. Alzheimer’s disease (AD) and Parkinson’s disease (PD). Genome-wide single nucleotide polymorphism (SNP; ∼5.5M sites) and DNAm (∼850K CpG sites) data were generated from whole blood (n=1,058), buccal (n=1,527) and saliva (n=837) specimens. We identified between 11 and 15 million genome-wide significant (p<10-14) SNP-CpG associations in each tissue. Combining these meQTL GWAS results with recent AD/PD GWAS summary statistics by MR strongly suggests that the previously described associations between PSMC3, PICALM, and TSPAN14 and AD may be founded on differential DNAm in or near these genes. In addition, there is strong, albeit less unequivocal, support for causal links between DNAm at PRDM7 in AD as well as at KANSL1/MAPT in AD and PD. Our study adds valuable insights on AD/PD pathogenesis by combining two high-resolution “omics” domains, and the meQTL data shared along with this publication will allow like-minded analyses in other diseases.
Competing Interest Statement
A detailed list of all competing interests is provided in the main text.
Funding Statement
Part of this research was funded by the EU Horizon 2020 Grant: Healthy minds 0-100 years: Optimising the use of European brain imaging cohorts (Lifebrain; grant #732592 to A.M.F., K.B.W., U.L., D.B.F., and L.B.), the Cure Alzheimers Fund (CIRCUITS-AD to L.B.), and the Deutsche Forschungsgemeinschaft (DFG; grant #DE842/7-1 to I.D.). Additional support was provided by the German Federal Ministry of Education and Research (for the BASE-II/GendAge studies) under grant numbers #01UW0808; #16SV5536K, #16SV5537, #16SV5538, #16SV5837, #01GL1716A and #01GL1716B. Further support came from the Norwegian Research Council (to K.B.W., A.M.F.), the National Association for Public Health's dementia research program, Norway (to A.M.F.), the European Research Council's Starting (grant agreement 283634 to A.M.F. and 313440 to K.B.W.) and consolidator Grant Scheme (grant #771355 to K.B.W. and #725025 to A.M.F.), the EU Joint Programme Neurodegenerative Disease Research 2021 (JPND2021, EPIC4ND project to C.M.L.) and the DFG (LI 2654/2-1 to C.M.L.). C.M.L. was supported by a Heisenberg grant of the DFG (LI 2654/4-1). Dr. D. Bartres-Faz was partly supported by the Barcelona Brain Health Initiative and Institute Guttmann and an ICREA Academia 2019 Research Award by the Catalan Government. Dr. A. Pascual-Leone was partly supported by the Barcelona Brain Health Initiative and Institute Guttmann, the National Institutes of Health (R01AG076708, R01AG059089, R03AG072233, and P01 AG031720), and the Bright Focus Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committees of University of Luebeck (approval number: 19-391A), Charite-Universitaetsmedizin Berlin (approval numbers: EA2/144/16, EA2/029/09), Unio Catalana d'Hospitals, Barcelona (approval number: CEIC 17/06), and the Regional Ethical Committee of South East Norway gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
All results of this study have been made available on Zenodo (URL: https://doi.org/10.5281/zenodo.10410506). Together with the AD/PD summary statistics from Bellenguez et al. (ref. 1) and Nalls et al. (ref. 2) these allow a full reproduction of all MR (incl. SMR) and colocalization analyses presented in this study. Sharing of individual-level genome-wide SNP genotyping and DNAm profiling data is restricted by study-specific access policies. Interested researchers can contact the steering committees of the respective studies to inquire about access: 1. BASE-II: [lmueller{at}mpib-berlin.mpg.de], 2. BBHI: [dbartres{at}ub.edu], 3. LCBC [k.b.walhovd{at}psykologi.uio.no]. Requested data will be made available pending appropriate institutional data protection security measures and ethical approval of the requestor’s institution.